Children and adolescents with homozygous beta-thalassemia can be cured by transplantation of normal stem cells after eradication of the thalassemic hematopoietic system. In an attempt to achieve durable engraftment and to minimize regimen-related toxicity (RRT), we have initiated a fludarabine-based pilot protocol not containing cyclophosphamide. Between 1999 and 2004, five children with beta-thalassemia major were enrolled. Median age at transplantation was 11.5 years (range 4-14 years). Three patients received conditioning with fludarabine (30 mg/m 2 /day Â 6), oral busulfan (3.5 mg/kg/day Â 4), and ATG rabbit Fresenius (10 mg/kg/day Â 4). Two children received intravenous busulfan instead of oral busulfan at a dose of 2 Â 1.4 mg/kg/day Â 4 days. All children were transplanted with a fresh bone marrow graft from an HLA-identical sibling. Mean cell doses given were 3.7 Â 10 8 nucleated cells/kg BW (range 2.4-6.2 Â 10 8 /kg). Overall, 5/5 patients achieved donor engraftment and are alive and well. No GVHD exceeding grade I was observed, and 2/5 children maintained donor chimerism at 100%. One patient maintains mixed hematopoietic donor chimerism being between 94 and 97% nearly 5 years after transplant.
marrow transplantation; fludarabine; cyclophosphamide; busulfan; ATG The thalassemias are probably the most common singlegene disorder that cause a major health problem worldwide. 1 The diagnosis of b-thalassemia is usually made in early childhood, and standard treatment with hypertransfusion and iron chelation has reduced iron-induced organ damage and improved survival. 2 However, a lack of compliance has become the most important obstacle of these regimens.
To date, in the absence of clinically available gene therapy protocols, allogeneic HCT represents the only rational therapeutic modality to cure b-thalassemia. HCT from a genotypically identical family donor has dramatically improved the prognosis of patients with homozygous b-thalassemia. Young patients transplanted at an early stage of the disease were reported to have a disease-free survival of 91% and a mortality risk of 8%. 3 Unfortunately, when transplantation is performed on older, more severely iron overloaded patients, the outcome has been less satisfactory. In this group of patients the probability of thalassemia-free survival and mortality has been reported as 51 and 32%, respectively. 4 The Pesaro classification of b-thalassemia patients into three classes of risk for bone marrow transplantation (BMT) has greatly helped to estimate prognosis and tailor risk-adapted transplantation strategies. 4, 5 Higher-risk patients as defined by pre-existing liver damage and a history of inadequate chelation therapy have experienced treatment-related mortality (TRM) of up to 47%. Attempts to reduce TRM using regimens containing less cyclophosphamide resulted in a mortality rate as low as 18%; however, rejection rate increased from 12 to 30% in these patients. 6 In this context the main problem was rejection, defined as a return of the thalassemic erythropoiesis. Although the preparative regimens of these studies varied, both over time and between transplant centers, most patients received a combination including busulfan and cyclophosphamide. Cyclophosphamide predominantly has been included in preparative regimens for its potent immunosuppressive activity. However, specific metabolites of cyclophosphamide are associated with increased toxicity and mortality after conditioning, especially in combination with totalbody irradiation. 7 These experiences provided the rationale to replace cyclophosphamide with a less toxic immunosuppressive combination of Fludarabine and ATG.
The goal of this pilot study was to determine whether a combination of 180 mg/m 2 fludarabine, ATG, and 14 mg/kg busulfan can provide donor-derived engraftment after allogeneic BMT from matched related family donors without an increased incidence and severity of transplantrelated complications.
Patients, materials, and methods
Patients represented five consecutive referrals of children with homozygous b-thalassemia to the BMT Unit of the Childrens' Hospital, Hannover Medical University. All patients received full marrow from HLA-identical siblings. After detailed explanation of the procedure and its risks, informed consent was obtained from the parents. Particular emphasis was placed on the option of continuing conventional disease management with transfusions and chelation therapy. Pre transplant characteristics of the patients are summarized in Table 1 . Prior to transplantation, all patients underwent a complete check-up and were assigned to one of three classes of risk according to slightly modified criteria proposed earlier by Lucarelli. 4 Risk factors were (1) hepatomegaly, (2) portal fibrosis as diagnosed by ultrasonographic examination (not by liver biopsy as originally described) and (3) the quality of pre transplantation iron chelation. Four patients were assigned to risk group 2 and one patient to risk group 3.
HLA typing and donor/recipient matching Molecular typing of patients and family members was performed by extracting DNA from whole blood samples. Alleles at the HLA-A, -B, -Cw, -DRB1, -DRB3, DRB4, -DRB5, -DQA1, -DQB1, and -DPB1 loci were identified by polymerase chain reaction (PCR) single strand polymorphism and sequence-based typing. Amplification and sequencing of HLA class I and class II were performed as previously described. 8, 9 Transplantation regimen, GVHD prophylaxis, and supportive therapy
The first three patients received conditioning with fludarabine (30 mg/m 2 /day on 6 consecutive days), oral busulfan (3.5 mg/kg/day on 4 consecutive days), and 10 mg/kg/day ATG (rabbit Fresenius) on 4 consecutive days. The two following children received intraveneous busulfan instead of oral busulfan at a dose of 2 Â 1.4 mg/kg/day on 4 consecutive days. All children received an unmanipulated bone marrow graft from an HLA-identical sibling. Mean cell doses transplanted were 3.7 Â 10 8 nucleated cells/kg BW (range 2.4-6.2 Â 10 8 /kg). All children received 3 mg/kg per day cyclosporine (CSA) intravenously from day -2 and short-term methotrexate (MTX) for graft-versus-host disease (GVHD) prophylaxis as described earlier. 10 CSA was switched to the oral form as soon as possible and was intended to be tapered by 10% per week starting at day þ 60. All patients were treated in positive-pressure isolation rooms and received nonabsorbable oral antibiotics and a low-bacteria diet. Supportive therapy consisted of Pneumocystis carinii propylaxis starting after engraftment with oral cotrimoxazole, a first generation cephalosporine as standard antibiotic prophylaxis, and defibrotide as a preventive agent against venous occlusive disease (VOD). CMV reactivation was monitored either by expression of the pp65 antigen or by quantitative PCR. Empiric broadspectrum antibiotic therapy was started when patients became febrile, and antifungal therapy was added in the presence of either clinical evidence of fungal infection or fever persisting after 3 days of antibiotic therapy. All blood products administered after transplantation were irradiated with 30 Gy. Neutrophil and platelet engraftment were defined as the first of 3 consecutive days with an absolute neutrophil count (ANC) of more than 0.5 Â 10 9 /l and platelets more than 50 Â 10 9 /l, respectively. Red cell recovery was defined by reticulocyte counts of 420/nl. Acute and chronic GVHD were graded according to the Seattle criteria.
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Monitoring of chimerism
Chimerism was documented by in situ Y chromosome hybridization of either bone marrow or blood samples in sex-mismatched donor/recipient pairs, by analysis of a variable number of tandem repeat (VNTR) polymorphism and by microsatellite analysis of bone marrow and/or blood samples in the case of sex-matched pairs.
Results
Engraftment
Between 1999 and 2004 five patients were transplanted from a HLA-identical sibling. All patients were alive and independent of transfusions when this report was written. Neutrophil engraftment occurred in all patients after a median of 17 days (range: 16-28 days). Platelet and red cell recovery was reached after a median of 31 days (range: 22-25 days) and 21 days (range: 17-27 days), respectively.
GVHD
The incidence of grade II-IV acute GVHD within this small cohort of children was 0%. No patient received donor lymphocyte infusions. Chronic GVHD was not observed.
Regimen related toxicity (RRT)
Two to five children experienced no toxicities 4grade I. All other patients experienced grade III-IV mucositis which required selective intubation in one of the patients. One of the older patients (14 years old at the time of transplantation, risk group 2) developed VOD, which resolved under treatment with defibrotide and strict fluid management. As a consequence, all the following patients were treated prophylactically with defibrotide beginning one day before the preparative regimen was started. None of the consecutive patients had VOD.
Chimerism
Three of the five reported children developed mixed hematopoietic chimerism within the first 50 days after transplantation. Therefore, CSA was started to be tapered before day þ 60 in those children. In all these three children donor-derived hematopoiesis increased from 75, 95, and 62 to 100, 97, and 89%, respectively. Follow-up times of these patients with early development of mixed hematopoietic chimerism are 2, 3, and 20 months. Results are summarized in Table 2 .
Discussion
We present first results on five children with b-thalassemia that received a fludarabine-based conditioning regimen without cyclophosphamide and total body irradiation for allogeneic HCT from an HLA-identical sibling. After a median follow-up time of 25 months all children are alive, have experienced acceptable treatment-related toxicity, and show donor-derived hematopoiesis between 73 and 100%. Being aware of the relative short follow-up, we hypothesize that this regimen has the potential to decrease the incidence of typical late effects associated with alkylating agents (cyclophosphamide) and irradiation such as, infertility, deficiencies of the endocrine system, cataract formation, and secondary malignancies.
To date the results of the Pesaro group represent one of the largest experiences with children undergoing HCT and being categorized as risk group 3. Until recently the post transplantation outcome of higher-risk children was significantly hampered due to nonrejection mortality. 4, 12 Subsequent studies suggested that the transplant-associated mortality within this risk group could be reduced from 47 to 18% by decreasing the total dose of cyclophosphamide given during the preparative regimen. However, this reduction was achieved at the expense of a rejection rate increasing from 12 to 30%. 12 On a molar basis and relative to other toxicities cyclophosphamide has shown to be the most immunosuppressive anticancer drug of any type. 13 Given at the very high doses (200 mg/kg or greater) as a single agent as used in preparation regimens for BMT, cyclophosphamide rarely causes cumulative damage to the bone marrow reflecting its stem cell sparing properties.
14 Therefore, this compound has been primarily used in BMT for its immunosuppressive and antileukemic properties. The dose-limiting toxicity of the drug seems to be cardiac toxicity. 15 In contrast to cyclophosphamide, busulfan has a potent myeloablative effect. In combination, these two drugs laid the basis for the most commonly used radiationfree preparative regimen used in BMT. 16 Unfortunately, the combination of cyclophosphamide and busulfan is prone to mediate endothelial damage of the small liver venules resulting in VOD. 17 Patients with thalassemia and portal fibrosis due to iron overload seem to be especially prone to liver toxicity caused by alkylating agents. 4 Therefore, we started a pilot protocol substituting cyclophosphamide completely by fludarabine and ATG. It consisted of a total of 180 mg/m 2 fludarabine, 14 mg/kg oral busulfan, and 40 mg/kg/day ATG (Rabbit Fresenius). Fludarabine is a purine analog with known inhibitory effects on lymphocyte proliferation. This drug has shown very few extramedullary toxicity in dose ranges between 90 and 125 mg/m 2 , although side effects involving the central nervous system are known to occur at higher doses. 18, 19 Since the incidence of children with b-thalassemia is relatively small in northern Germany, the decision to enroll all patients with an HLA-identical sibling donor on this protocol, irrespective of the risk group was made. Only one of the five patients was classified as risk group 3. This patient was one of the two patients who received intravenous busulfan instead of the oral formulation. Interestingly, the latter two children went through the transplantation procedure with no toxicities greater than grade I. The higher-grade mucositis and the only case of significant VOD were observed in children that were conditioned with oral busulfan. It is impossible to comment on the significance of this observation since the numbers are small and busulfan serum levels were not monitored during the preparative regimen.
Sodani et al 6 recently reported on their results in patients with class three thalassemia aged younger than 17 years who received transplants from HLA-identical donors. As a consequence of the high rejection rates with lower doses of cyclophosphamide an alternative approach was chosen. Cyclophosphamide was kept as part of the preparative regimen at a reduced cumulative dose and fludarabine was added. In an attempt to further enhance both immunosuppression and eradication of the thalassemic clone, hydroxyurea and azathioprine were given in addition. This regimen that was given to 33 consecutive class 3 patients was tolerated well and the incidence of recurrent thalassemia decreased from 30 to 8%.
Vaughan and McDonald found a strong correlation between blood levels of various cyclophosphamide meta- bolites and VOD. It was postulated that the formation of these metabolites depletes the liver of glutathione (GSH) resulting in significant toxicity. 7, 20 Fludarabine, however, is not known to deplete the GSH content. This might be of increasing importance in patients entering HCT with pre-existing liver damage. In addition, nucleoside analogs such as fludarabine are reported to exert synergistic effects with alkylating agents such as busulfan. 21 The described observation formed a compelling argument for us to replace cyclophosphamide completely by fludarabine in a busulfan-based conditioning regimen for children and adolescents with thalassemia. Early mixed chimerism rates especially after intravenous busulfan-fludarabine as reported by others are mirrored by our limited experience with a small group of patients. 22 However, these chimerism results seem similar to what has been reported after intravenous busulfan-cyclophosphamide. 23 Others used similar concepts. Iannone and Walters used fludarabine and 200 cGy of total body irradiation as a preparative regimen for seven children receiving a graft from an HLAidentical sibling. Six patients had sickle cell disease and 1 patient b-thalassemia. Post-HCT immunosuppression consisted of mycophenolate mofetil and CSA or tacrolimus. This regimen was well tolerated and resulted in donor chimerism between 25 and 85%. However, after discontinuation of the immunosuppression all patients lost their graft and had full autologous recovery. 24 A very similar regimen was recently reported by Horan et al. 25 In an attempt to keep treatment-related toxicities low and to decrease the risk of graft rejection at the same time, the same group added ATG to the preparative regimen used. Donor chimerism was 15-100% post transplant. Unfortunately all but one patient lost their graft after post-HCT immunosuppression had been tapered. Earlier Hongeng and Jootar reported the case of successful HCT in a 10-year-old girl who had Pesaro class 3 beta-thalassemia major. The conditioning regimen consisted of busulfan, fludarabine, antilymphocyte globulin and total lymphoid irradiation. The girl was alive, well and fully engrafted 1 year after transplant. 26 This last report adds to the concept that apart from immunosuppressive drugs the preparative regimen for hemoglobinopathies should contain an agent that creates 'marrow space' such as busulfan.
ATG has been used as part of the preparatory regimen prior to the infusion of donor cells to decrease the incidence of graft rejection. Animal experiments have originally shown the synergistic immunosuppressive effects between ATG and alkylating agents such as procarbazine and cyclophosphamide. 27 Consecutively, regimens of ATG and cyclophosphamide were developed to be used for rescuing patients who had rejected their first graft. 28 As a result of the success of ATG and cyclophosphamide in second transplants, this combination was increasingly used as conditioning regimen for first transplants. In a later attempt to maintain the strong immunosuppression provided by cyclophosphamide, but avoiding its known toxicities, Slavin et al 29 at the Hadassah University in Israel used a regimen that consisted of fludarabine, busulfan (8 mg/kg), and ATG in a relatively young group of 26 patients. This preparative regimen was implemented as a nonmyeloablative approach. In nine patients this regimen resulted in stable partial chimerism; complete donor-derived hematopoiesis was achieved in 17 patients. In our small patient cohort even higher doses of busulfan resulted in a mixed hematopoietic chimerism in three of the five patients. Whereas the patients reported on by Slavin were mostly heavily pretreated for malignant diseases, our patients started HCT with an intact immune system. This observation stresses the importance of considering previous immunosuppressive therapies when a preparative regimen is selected. Since the course of mixed chimerism early after transplantation is difficult to predict, we decided to decrease post transplant immunosuppression rapidly in those three patients. As a consequence, all of them have either increasing levels of donor-derived hematopoiesis or achieved complete chimerism. None of them developed GVHD after early discontinuation of CSA. All patients that developed a mixed hematopoietic chimerism did so within the first 50 days post transplant. Therefore, conducting routine chimerism studies with relatively short time intervals early after HCT seems to be an important tool to manage this group of patients. However, this approach might be problematic in the unrelated transplant settings. Rapid and early decrease of post transplant immunosuppression may result in more complications caused by GVH.
The current series of five children gave encouraging evidence that an intravenous busulfan-fludarabine combination seems to be a feasible approach for matched family donor transplantations for patients suffering from thalassemia. Although the authors are aware of the small patient number and short follow-up of at least two patients presented in this case series (graft rejection in thalassemia patients has been reported as far out as 1 year post-HCT), RRT were acceptable and even negligible in the case where intravenous busulfan was used. The data will be the basis for further prospective studies in larger patient cohorts.
